CD8A and hepatocellular carcinoma: Indeed, combining RFA with a CTLA-4 inhibitor has demonstrated clinical activity in a phase 1 trial of hepatocellular carcinoma with a clear increase in CD8+ T-cells in patients who showed a clinical benefit [27].